Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline for Chronic Pain Due to Endometriosis
NCT03928288Phase 2Completed
- Sponsor
- Boston Children's Hospital
- Start
- Dec 2019
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in endometriosis comparing Cabergoline with Placebo (2 arms). Primary endpoints: Brief Pain Inventory Interference Scale at 24 weeks, Visual Analog Scale at 24 weeks and 1 more. Started Dec 2019; status: completed.
02
Drugs
cabergoline
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT03928288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03928288.